Top

Published in:

01-12-2020 | Systemic Lupus Erythematosus | Review

A meta-analysis of secondary osteoporosis in systemic lupus erythematosus: prevalence and risk factors

Authors: Chaoyu Gu, Rui Zhao, Xiaomei Zhang, Zhifeng Gu, Wei Zhou, Yilin Wang, Jiaxin Guo, Yanfeng Bao, Chi Sun, Chen Dong, Jianlin Gao

Published in: Archives of Osteoporosis | Issue 1/2020

Abstract

Purpose

This study aimed to evaluate the prevalence and risk factors of secondary osteoporosis (OP) in patients with systemic lupus erythematosus (SLE) and provide a theoretical basis for clinical prevention and treatment of SLE.

Methods

Take systematic review and meta-analysis of relevant studies. Data sources are CINAHL databases, PubMed, Embase, Wan Fang, Weipu, and CNKI databases. Eligibility criteria are cross-sectional or case–control studies which analyzed the prevalence and risk factors of OP in SLE. Two authors independently screened all studies; a third author verified and identify controversial studies. The quality of the included articles was evaluated. Stata 11 and Rev-Man 5.2 software were used for data processing.

Results

Thirty-one articles were included, with a total sample size of 3089 SLE, including 529 OP cases and 2560 non-OP cases. Meta-analysis showed that the prevalence of OP among SLE was 16% (95% CI (0.12, 0.19)). The risk of OP in SLE cases compared with controls was significantly greater with OR of 2.03 (95% CI 1.33–3.10, P = 0.001). Age, disease duration, cumulative glucocorticoid dose, duration of glucocorticoid therapy, SLICC, and menopause had significant differences between two groups. No statistical differences of daily glucocorticoid dose, SLEDAI, and BMI were found between OP and non-OP cases.

Conclusions

Our study found a statistically significant increased risk of OP in SLE patients compared with controls. SLE patients should be actively screened for OP and its consequences. Larger longitudinal studies are needed to confirm this possible association.

The prevalence of OP in SLE was 16%. Compared with controls, the risk of OP in SLE was 2.03. There were significant differences of age, disease duration, cumulative glucocorticoid dose, time of glucocorticoid, SLICC, and menopause, while daily glucocorticoid dose, SLEDAI, and BMI had no statistical differences between OP and non-OP cases.

Wang H, Wang J, Xia Y (2017) Defective suppressor of cytokine signaling 1 signaling contributes to the pathogenesis of systemic lupus erythematosus. Front Immunol 8:1292. https://doi.org/10.3389/fimmu.2017.01292CrossRefPubMedPubMedCentral

Wu H, Zhao M, Chang C, Lu Q (2015) The real culprit in systemic lupus erythematosus: abnormal epigenetic regulation. Int J Mol Sci 16(5):11013–11033. https://doi.org/10.3390/ijms160511013CrossRefPubMedPubMedCentral

Khaniukov O, Yehudina Y, Kalashnykova O, Sapozhnychenko L (2018) Management of patients with systemic lupus erythematosus in the prepregnancy and antenatal periods: challenges and solutions (review). Georgian Med News 280–281:54–61

Ruiz-Irastorza G, Danza A, Khamashta M (2012) Glucocorticoid use and abuse in SLE. Rheumatology (Oxford) 51(7):1145–1153. https://doi.org/10.1093/rheumatology/ker410CrossRef

Xiao Y, Li K, Wang Z, Fu F, Shao S, Song F, Zhao J, Chen W, Liu Q, Xu J (2019) Pectolinarigenin prevents bone loss in ovariectomized mice and inhibits RANKL-induced osteoclastogenesis via blocking activation of MAPK and NFATc1 signaling. J Cell Physiol. https://doi.org/10.1002/jcp.28079

Bultink IE (2012) Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res 64(1):2–8. https://doi.org/10.1002/acr.20568CrossRef

Ji Z, Zhang Z, Bao C, Zhao D, Lin J, Wu H, He D, Du H, Jiang L (2014) The epidemiological investigation on glucocorticoid-induced osteoporosis. Chin J Rheumatol 8:520–524. https://doi.org/10.3760/cma.j.issn.0578-1426.2017.03.006

Dey M, Bukhari M (2018) Predictors of fracture risk in patients with systemic lupus erythematosus. Lupus 27(9):1547–1551. https://doi.org/10.1177/0961203318768886CrossRefPubMed

Di Munno O, Mazzantini M, Delle Sedie A, Mosca M, Bombardieri S (2004) Risk factors for osteoporosis in female patients with systemic lupus erythematosus. Lupus 13(9):724–730. https://doi.org/10.1191/0961203303lu1097oaCrossRefPubMed

10.

Bultink IEM (2018) Bone disease in connective tissue disease/systemic lupus erythematosus. Calcif Tissue Int 102(5):575–591. https://doi.org/10.1007/s00223-017-0322-zCrossRefPubMed

11.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006–1012. https://doi.org/10.1016/j.jclinepi.2009.06.005CrossRefPubMed

12.

Cramarossa G, Urowitz MB, Su J, Gladman D, Touma Z (2017) Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus. Lupus 26(4):365–372. https://doi.org/10.1177/0961203316664597CrossRefPubMed

13.

Bundhun PK, Kumari A, Huang F (2017) Differences in clinical features observed between childhood-onset versus adult-onset systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore) 96(37):e8086. https://doi.org/10.1097/MD.0000000000008086CrossRef

14.

Gibofsky A (2012) Comparative effectiveness of current treatments for rheumatoid arthritis. Am J Manag Care 18(13 Suppl):S303–S314PubMed

15.

Bultink IE, Lems WF, Kostense PJ, Dijkmans BA, Voskuyl AE (2005) Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 52(7):2044–2050. https://doi.org/10.1002/art.21110CrossRefPubMed

16.

Carli L, Tani C, Spera V, Vagelli R, Vagnani S, Mazzantini M, Di Munno O, Mosca M (2016) Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. Lupus Sci Med 3(1):e000098. https://doi.org/10.1136/lupus-2015-000098CrossRefPubMedPubMedCentral

17.

Chong HC, Chee SS, Goh EM, Chow SK, Yeap SS (2007) Dietary calcium and bone mineral density in premenopausal women with systemic lupus erythematosus. Clin Rheumatol 26(2):182–185. https://doi.org/10.1007/s10067-006-0258-6CrossRefPubMed

18.

Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, Silverman ED (2007) Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum 56(6):1966–1973. https://doi.org/10.1002/art.22691CrossRefPubMed

19.

Ding C, Sun L, Wang H, Lin H, Zhang X (2002) Determinants of bone mineral density in systemic lupus erythematosus. Chin J Rheumatol 6(3):192–194. https://doi.org/10.3760/j:issn:1007-7480.2002.03.012CrossRef

20.

Pons F, Peris P, Guanabens N, Font J, Huguet M, Espinosa G, Ingelmo M, Munoz-Gomez J, Setoain J (1995) The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women. Br J Rheumatol 34(8):742–746CrossRef

21.

Furukawa M, Kiyohara C, Tsukamoto H, Mitoma H, Kimoto Y, Uchino A, Nakagawa M, Oryoji K, Shimoda T, Akashi K, Harada M, Horiuchi T (2011) Prevalence of and risk factors for low bone mineral density in Japanese female patients with systemic lupus erythematosus. Rheumatol Int 31(3):365–376. https://doi.org/10.1007/s00296-009-1244-5CrossRefPubMed

22.

Wang G, Li X, Li X, Wang G, Tao J, Ma Y (2017) The effect of long-term low dose prednisone on bone mineral density in patients with systemic lupus erythematosus. Chin J Intern Med 56(3):179–183. https://doi.org/10.3760/cma.j.issn.0578-1426.2017.03.006

23.

Bhattoa HP, Bettembuk P, Balogh A, Szegedi G, Kiss E (2002) Bone mineral density in women with systemic lupus erythematosus. Clin Rheumatol 21(2):135–141CrossRef

24.

Liang J, Jiang N, Xu Z, Lu X, Liu X, Chen S (2006) The influence of long-term glucocorticoid use on bone mineral density in premenopausal women with SLE. Chin J Osteoporos 12(1):57–58,61. https://doi.org/10.3969/j.issn.1006-7108.2006.01.017CrossRef

25.

Shen L, Liu Q, Yu L, Huang A (2004) Multivariable statistical analysis of osteoporosis in patients with systemic lupus erythematosus. Chin J Rheumatol 8(2):92–96. https://doi.org/10.3760/j:issn:1007-7480.2004.02.008CrossRef

26.

Pineau CA, Urowitz MB, Fortin PJ, Ibanez D, Gladman DD (2004) Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus 13(6):436–441. https://doi.org/10.1191/0961203303lu1036oaCrossRefPubMed

27.

Ye Q, Xiong Y, Cao X, Du W (2013) Bone mineral density in 42 female patients with systemic lupus erythematosus. Chin J Diffic and Compl Cas 12(4):312–313. https://doi.org/10.3969/j.issn.1671-6450.2013.04.024CrossRef

28.

Sun YN, Feng XY, He L, Zeng LX, Hao ZM, Lv XH, Pu D (2015) Prevalence and possible risk factors of low bone mineral density in untreated female patients with systemic lupus erythematosus. Biomed Res Int 2015:510514. https://doi.org/10.1155/2015/510514CrossRefPubMedPubMedCentral

29.

Zhu X, Liang J, Lin B, Zhang J, Tan G (2000) Measurement of bone mineral density in premenopausal women with systemic lupus erythematosus. Chin J Dermatol 3(1):12. https://doi.org/10.3760/j.issn:0412-4030.2000.01.004CrossRef

30.

Liu X, Zhu X, Li S (2000) Detection and analysis of bone mineral density in patients with systemic lupus erythematosus. J Nurs 15(1):14–15. https://doi.org/10.3969/j.issn.1001-4152.2000.01.005CrossRef

31.

Hou X, Zhang M, Cui L (2015) Serum immunological risk factors for osteoporosis in patients with systemic lupus erythematosus. Shandong Medical Journal 24:79–80. https://doi.org/10.3969/j.issn.1002-266X.2015.24.035CrossRef

32.

Yeap SS, Fauzi AR, Kong NC, Halim AG, Soehardy Z, Rahimah S, Chow SK, Goh EM (2009) Influences on bone mineral density in Malaysian premenopausal systemic lupus erythematosus patients on corticosteroids. Lupus 18(2):178–181. https://doi.org/10.1177/0961203308094995CrossRefPubMed

33.

Yee CS, Crabtree N, Skan J, Amft N, Bowman S, Situnayake D, Gordon C (2005) Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 64(1):111–113. https://doi.org/10.1136/ard.2003.018127CrossRefPubMedPubMedCentral

34.

Luo Z, Wu J, Huang L, Liao T, He Y (2014) Study on the relationship between inflammatory states of SLE and osteoporosis. J Mod Med Health 18:2730–2732. https://doi.org/10.3969/j.issn.10095519.2014.18.004

35.

He W, Li J, Li B, Ye Z, Guo F, Tan D, Xie Y, Xu S (2009) Influencing factors of bone mineral density in premenopausal women with rheumatism. Journal of Pratical Medcine 25(3):394–396. https://doi.org/10.3969/j.issn.1006-5725.2009.03.023CrossRef

36.

Sui P, Li X (2008) Changes of bone mineral density in patients with systemic lupus erythematosus before and after hormone therapy. J Jining Med Univ 31(4):298–299. https://doi.org/10.3969/j.issn.1000-9760.2008.04.013

37.

Yu J (2015) Effects of different doses of glucocorticoid maintenance therapy on bone mineral density and bone metabolism in patients with systemic lupus erythematosus. Bengbu Medical College

38.

Liang H (2010) Bone mineral density changes and influencing factors in systemic lupus erythematosus. . Shantou University

39.

Mendoza-Pinto C, García-Carrasco M, Sandoval-Cruz H, Escárcega RO, Jiménez-Hernández M, Etchegaray-Morales I, Soto-Vega E, Muñoz-Guarneros M, López-Colombo A, Delezé-Hinojosa M, Cervera R (2008) Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus. Clin Rheumatol 28(1):65–70. https://doi.org/10.1007/s10067-008-0984-zCrossRefPubMed

40.

Banno S, Matsumoto Y, Naniwa T, Hayami Y, Sugiura Y, Yoshinouchi T, Ueda R (2002) Reduced bone mineral density in Japanese premenopausal women with systemic lupus erythematosus treated with glucocorticoids. Mod Rheumatol 12(4):323–328. https://doi.org/10.3109/s101650200057CrossRefPubMed

41.

Becker A, Fischer R, Scherbaum WA, Schneider M (2001) Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage. Lupus 10(11):809–814. https://doi.org/10.1177/096120330101001108CrossRefPubMed

42.

Yuan Q (2014) Bone mass and related factors in 100 female patients with diffuse connective tissue disease. Zhejiang University

43.

Sinigaglia L, Varenna M, Binelli L, Zucchi F, Ghiringhella D, Gallazzi M, Limonta M, Zeni S, Fantini F (1999) Determinants of bone mass in systemic lupus erythematosus: a cross sectional study on premenopausal women. J Rheumatol 26(6):1280–1284PubMed

44.

Wang Z (2017) The research of osteoporosis in patients with untreated systemic lupus erythematosus. Hebei Medical University

45.

Le B, Waller JL, Radhakrishnan R, Oh SJ, Kheda MF, Nahman NS Jr, Carbone L (2018) Osteoporotic fractures in patients with systemic lupus erythematosus and end stage renal disease. Lupus 27(1):17–24. https://doi.org/10.1177/0961203317709953CrossRefPubMed

46.

Bultink IE, Lems WF (2016) Lupus and fractures. Curr Opin Rheumatol 28(4):426–432. https://doi.org/10.1097/BOR.0000000000000290CrossRefPubMed

47.

Briot K, Geusens P, Em Bultink I, Lems WF, Roux C (2017) Inflammatory diseases and bone fragility. Osteoporos Int 28(12):3301–3314. https://doi.org/10.1007/s00198-017-4189-7CrossRefPubMed

48.

Stojan G, Petri M (2017) The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years? Curr Treatm Opt Rheumatol 3(3):164–172. https://doi.org/10.1007/s40674-017-0069-8CrossRefPubMedPubMedCentral

49.

Balasubramanian A, Wade SW, Adler RA, Saag K, Pannacciulli N, Curtis JR (2018) Glucocorticoid exposure and fracture risk in a cohort of US patients with selected conditions. J Bone Miner Res 33(10):1881–1888. https://doi.org/10.1002/jbmr.3523CrossRefPubMed

50.

Sarkissian A, Sivaraman V, Bout-Tabaku S, Ardoin SP, Moore-Clingenpeel M, Mruk V, Steigelman H, Morris K, Bowden SA (2019) Bone turnover markers in relation to vitamin D status and disease activity in adults with systemic lupus erythematosus. Lupus 28(2):156–162. https://doi.org/10.1177/0961203318815593CrossRefPubMed

51.

Seguro LP, Casella CB, Caparbo VF, Oliveira RM, Bonfa A, Bonfa E, Pereira RM (2015) Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients. Osteoporos Int 26(2):459–467. https://doi.org/10.1007/s00198-014-2860-9CrossRefPubMed

52.

Vitku J, Kolatorova L, Franekova L, Blahos J, Simkova M, Duskova M, Skodova T, Starka L (2018) Endocrine disruptors of the bisphenol and paraben families and bone metabolism. Physiol Res 67(Supplementum 3):S455–S464CrossRef

53.

Salman-Monte TC, Torrente-Segarra V, Munoz-Ortego J, Mojal S, Carbonell-Abello J (2015) Prevalence and predictors of low bone density and fragility fractures in women with systemic lupus erythematosus in a Mediterranean region. Rheumatol Int 35(3):509–515. https://doi.org/10.1007/s00296-014-3087-yCrossRefPubMed

54.

Sciascia S, Mompean E, Radin M, Roccatello D, Cuadrado MJ (2017) Rate of adverse effects of medium- to high-dose glucocorticoid therapy in systemic lupus erythematosus: a systematic review of randomized control trials. Clin Drug Investig 37(6):519–524. https://doi.org/10.1007/s40261-017-0518-zCrossRefPubMed

55.

Gracanin AG, Markovic I, Loncarevic J, Golob M, Morovic-Vergles J (2015) Bone mineral density in patients with systemic lupus erythematosus--our results. Reumatizam 62(2):16–21PubMed

Title: A meta-analysis of secondary osteoporosis in systemic lupus erythematosus: prevalence and risk factors
Authors: Chaoyu Gu
Rui Zhao
Xiaomei Zhang
Zhifeng Gu
Wei Zhou
Yilin Wang
Jiaxin Guo
Yanfeng Bao
Chi Sun
Chen Dong
Jianlin Gao
Publication date: 01-12-2020
Publisher: Springer London
Keywords: Systemic Lupus Erythematosus
Glucocorticoid
Osteoporosis
Osteoporosis
Published in: Archives of Osteoporosis / Issue 1/2020
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-019-0667-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A meta-analysis of secondary osteoporosis in systemic lupus erythematosus: prevalence and risk factors

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Recognizing osteoporotic vertebral deformity on frontal view radiograph: a cohort analysis and a pictorial review

Impact of changes in fat mass and lean soft tissue on bone mineral density accrual in adolescents engaged in different sports: ABCD Growth Study

Osteoporosis screening using computed tomography for men with prostate cancer: results of a prospective study

Report on the Audit on Burden of Osteoporosis in Eight Countries of the Eurasian Region: Armenia, Belarus, Georgia, Moldova, Kazakhstan, the Kyrgyz Republic, the Russian Federation, and Uzbekistan

A surrogate FRAX model for the Kyrgyz Republic

Vertebral fracture assessment by dual-energy X-ray absorptiometry along with bone mineral density in the evaluation of postmenopausal osteoporosis